Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Argentine Hemorrhagic Fever

Infectious and Parasitic Diseases

Argentine hemorrhagic fever, also known as O'Higgins disease or, in Argentina, mal de los rastrojos, is a hemorrhagic fever and zoonotic disease found in Argentina. It is caused by the Junin virus, an arenavirus closely related to the Machupo virus that causes Bolivian hemorrhagic fever, and its natural reservoir is the drylands vesper mouse, a rodent found in Argentina and Paraguay.

Facts
Classification
ICD-10 Chapter
I: Certain Infectious and Parasitic Diseases 1
Communicable or Non-communicable
Communicable 1
Transmission Route
Zoonotic 2
Causative Agent
Causative Agent (category)
Viral 2
Argentine Hemorrhagic Fever
Filter Results1 entry
Connections

Treated By

Source Convalescent plasma (Wikipedia)
Sources
1. Wikipedia: ICD-10
WikipediaList of chapters, Chapter I
Quote, List of chapters, Chapter I
Certain infectious and parasitic diseases
View the Source
2. Argentine hemorrhagic fever (Wikipedia)
  • Lead - causative-agent
    It is caused by the Junín virus (an arenavirus, closely related to the Machupo virus, causative agent of Bolivian hemorrhagic fever).
  • Lead section, transmission-route statement
    Argentine hemorrhagic fever (AHF) or O'Higgins disease, also known in Argentina as mal de los rastrojos (stubble disease) is a hemorrhagic fever and zoonotic infectious disease occurring in Argentina.
View the Source
Convalescent plasma (Wikipedia)
Treated By: Convalescent Plasma, Argentine hemorrhagic fever
Quote, Treated By: Convalescent Plasma, Argentine hemorrhagic fever
Convalescent plasma has been used during Argentine hemorrhagic fever epidemics; a double-blind, randomized clinical trial conducted from 1974 to 1978 demonstrated that patients treated with convalescent plasma within eight days of disease onset had a 15.4% lower absolute mortality rate than patients who received control plasma without neutralizing antibodies to Argentine
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.